Genolution

Genolution R&D per Employee

The R&D Spending per Employee of Genolution (225220.KQ) as of Nov 19, 2026 is 5.42 M KRW. In the previous year, R&D Spending per Employee was 19.21 M KRW — a change of -71.79% (lower).

R&D per Employee

5.42 MKRW

YoY

-71.79%

Last updated:

R&D Spending per Employee of Genolution is 2025 5.42 M KRW. R&D Spending per Employee of Genolution was 2024 19.21 M KRW. It decreases by -71.79% lower compared to the previous year.

The Genolution R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2020
5.32 M KRW
Jan 1, 2021
18.95 M KRW
Jan 1, 2022
17.42 M KRW
Jan 1, 2023
35.42 M KRW
Jan 1, 2024
19.21 M KRW
Jan 1, 2025
5.42 M KRW
The Genolution R&D per Employee history
YEARR&D per EmployeeYoY
5.42 MKRW-71.79%
19.21 MKRW-45.75%
35.42 MKRW+103.27%
17.42 MKRW-8.05%
18.95 MKRW+256.31%
5.32 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

R&D Spending per Employee of Genolution is 5.42 M KRW in 2025.

R&D Spending per Employee of Genolution changed from 19.21 M KRW to 5.42 M KRW, representing a -71.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Genolution since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Genolution

All Key Metrics — Genolution